---
schema_version: "secwatch.filing_event.v1"
accession: "0001299130-26-000005"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:47:38.136966+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PacBio Q4 revenue $44.6M (+14% YoY); full year $160M (+4%); record consumables

## Summary
- Q4 2025 revenue ~$44.6M vs $39.2M YoY; full year ~$160M vs $154M.
- Instrument revenue Q4 ~$17.3M (Q4'24 $15.3M); consumables ~$21.6M (Q4'24 $18.8M) a record.
- Vega placements 42 in Q4 vs 7 a year ago; Revio placements 21 vs 23.
- Ending cash $279.5M vs $389.9M; management cites reduced cash burn and SPRQ-Nx catalyst.
- PacBio presents at J.P. Morgan Healthcare Conference on Jan 12, 2026.

## SEC filing metadata
- accession: 0001299130-26-000005
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000129913026000005/0001299130-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000129913026000005/pacb-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001299130-26-000005
- JSON: https://secwatch.observer/filing/0001299130-26-000005.json
- Plain text: https://secwatch.observer/filing/0001299130-26-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.